<DOC>
	<DOCNO>NCT02830919</DOCNO>
	<brief_summary>This phase III clinical study conduct Brazilian research sit . It include study 314 participant diagnose primary knee OA accord classification criterion ACR . After washout period , participant randomize receive combination glucosamine sulfate + chondroitin sulfate bovine origin Eurofarma Laboratorios S.A. ( N= 157 ) combination glucosamine sulfate + chondroitin sulfate Zodiac Pharmaceuticals S.A. Condroflex ® ( N = 157 ) . The treatment period study 24 week . Each participant perform seven visit research site . The main evaluation improve pain target knee questionnaire Western Ontario McMaster Universities Osteoarthritis Index ( WOMAC ) quality life SF-12 questionnaire .</brief_summary>
	<brief_title>Clinical Study Non-inferiority With Participants Diagnosed With Primary Knee OA ( GLACIAL )</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Male female patient meet follow criterion enrol study : 1 . Aged ≥ 40 year . 2 . Clinical radiological diagnosis primary ( idiopathic ) arthrosis knee accord criterion American College Rheumatology ( ACR ) . 3 . Kellgren Lawrence radiological classification degree 2 3 xray kneetarget obtain 3 month prior screen visit study . 4 . Presence painful symptom target knee last 3 month due osteoarthritis . 5 . Visual analogue scale evaluation pain osteoarthritis knee research participant screen visit ≥ 40 mm 6 . Average score ≥ 40 mm subscale `` pain '' ( 0 100 mm ) target knee questionnaire Western Ontario McMaster Universities Osteoarthritis Index ( WOMAC ) , randomization visit . 7 . Functional class ACR I III . 8 . Signing Informed Consent Form ( ICF ) performance study procedure . Patients meet least one follow criterion exclude study : 1 . Diagnosis septic arthritis , inflammatory arthritis ( rheumatoid arthritis ) , gout , pseudogout , Paget 's disease , dysplasias congenital joint abnormality . 2 . Presence inflammatory signal ( edema , erythema joint effusion ) target knee , consider clinically significant investigator . 3 . Serious target knee joint misalignment , define investigator . 4 . Predominantly patellofemoral Osteoarthritis target knee . 5 . Historical severe trauma surgery ( include arthroscopy ) target knee 6 month screen visit . 6 . Planned Surgery target knee 7 . Symptomatic Osteoarthritis ipsilateral hip . 8 . Use nonsteroidal antiinflammatory , dipyrone opioid analgesic narcotic screen visit , washout period medicine less defined Protocol , randomization visit . 9 . Oral Glucocorticoids , intravenously intramuscularly 30 day prior screen visit . 10 . Intraarticular corticosteroid Injection and/or hyaluronic acid target knee 6 month prior screen visit . 11 . Use follow drug period describe , screen visit : 1 . Diacerein , chloroquine soybean avocado unsaponifiables extract last 3 month . 2 . Duloxetine hydrochloride last 30 day . 3 . Glucosamine Sulphate and/or chondroitin sulfate last 6 month . 4 . Strontium ranelate past 6 month . 12 . Historical allergy intolerance treatment study paracetamol . 13 . Physiotherapy irregular practice physical activity begin 3 month prior screen visit . 14 . Diagnosis fibromyalgia , collagenosis significative vascular/neurologica disease low limb may confuse analysis study . 15 . Body mass index ≥ 40 kg/m2 . 16 . Need use cane , crutches walker . 17 . Presence infectious hepatitis active history hepatitis medicinal product . 18 . Results ALT , AST total bilirubin fraction upper limit normal . 19 . Serum creatinine level upper limit normal . 20 . Fasting blood glucose &gt; 110 mg/dL glycated hemoglobin &gt; 6.5 % . 21 . Use anticoagulant . 22 . Consumption alcohol one dose day ( woman ) two dos day ( men ) . 23 . Presence serious disease control . 24 . Planned surgery occur period participation study . 25 . Presence pregnancy breastfeed . 26 . Women childbearing potential must agree use highly effective contraception . 27 . Participation clinical trial protocol within previous 12 month unless , investigator 's discretion , participation may imply direct benefit participant . 28 . Presence condition , investigator 's discretion , may consider participation patient inadequate study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Osteoarthritis knee</keyword>
	<keyword>Glucosamine sulfate</keyword>
	<keyword>Chondroitin sulfate</keyword>
</DOC>